Convening of Onxeo's Joint General Meeting on May 29, 2020 in Camera and Voting Procedures in the Covid-19 Context

Nachrichtenquelle: Business Wire (engl.)
27.04.2020, 17:45  |  122   |   |   

Regulatory News:

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo”, “the Company” or “the Group”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, informs its shareholders of the voting procedures at its joint general meeting on May 29, 2020 in the context of the coronavirus epidemic (Covid-19).

In order to comply with the restrictions on gatherings and travel imposed by the Government and ensure the safety of its shareholders and Onxeo's teams, the Board of Directors has decided to hold the Joint General Meeting on May 29, 2020 at 10:00 a.m., in camera, without the presence of any shareholders and other persons eligible to attend, pursuant to the provisions of Order no. 2020-321 of March 25, 2020.

The General Meeting will be webcast live via a web conferencing system, with a dedicated presentation (in French), and Onxeo will soon publish the login details in a separate press release.

Shareholders will thus be able to follow the management presentation and ask their questions via the web platform during the Q&A session, however, they will not be able to vote during the meeting.

In accordance with current regulations and the recent recommendations of the French stock-market authority (AMF), Onxeo shareholders are requested to cast their votes exclusively through distance voting prior to the General Meeting:

- internet voting will be available and must be used as a priority: the secure voting platforms Votaccess in France and Computershare in Denmark will open on May 7, 2020.

- alternatively, shareholders can also vote by postal ballot, in accordance with the terms and conditions indicated in the prior notice published in the BALO on April 24, 2020.

All the documents relating to this General Meeting will be available within the legal deadlines on the company's website, in the General Meetings section, and shareholders will be notified by a press release.

If you have any questions about voting procedures, please contact the Investor Relations team by e-mail at ag2020@onxeo.com.

Judith Greciet, Onxeo's Chief Executive Officer, said: “Onxeo's Annual General Meeting is a key moment for dialogue with our shareholders. Although this year the health context prevents us from organizing this meeting "in person", we wanted to facilitate the exchanges as much as possible, which will take place via a web conference during which Mrs. Danièle-Guyot Caparros, Mr. Nicolas Fellmann and myself will be present to answer your questions. In addition, for the first time, we are introducing Internet voting, in addition to the more random postal voting, given the current postal delays. The mobilisation of all our shareholders is key, the resolutions presented are necessary for the further development of our company, and we are counting on each of you to participate, remotely, at least by your votes and if possible at the presentation session on May 29.“

Seite 1 von 3
Onxeo Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Convening of Onxeo's Joint General Meeting on May 29, 2020 in Camera and Voting Procedures in the Covid-19 Context Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo”, “the Company” or “the Group”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel